ERBB2 and breast cancer: The ER+/HER2- BC patients included in the study had high-risk factors for recurrence (non-pCR and a CPS + EG score ≥ 3 in patients who received neoadjuvant therapy, or ≥ 4 positive lymph nodes after initial surgery).